We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




Radiotherapy Provides Relief for Patients with Painful Heel Spurs

By HospiMedica International staff writers
Posted on 08 Aug 2012
Patients with plantar fasciitis experience substantially less pain and improved quality of life following a standard dose of external beam radiation therapy, a commonplace cancer treatment similar to receiving an X-ray, according to a randomized, cooperative group study.

The study’s findings were published online July 31, 2012, in the International Journal of Radiation Oncology-Biology-Physics (Red Journal), the official scientific journal of the American Society for Radiation Oncology (ASTRO). More...
Approximately 8%-10% of the population has severe bone heel spurs, with the most common treatments for alleviating the pain being ice, heat, and various anti-inflammatory medications. Steroids and local anesthetics can be injected, and oral analgesic medications may be ordered, but most of these techniques have only provided short-term pain relief. The results of this study demonstrated that up to 80% of standard dose patients experienced complete pain relief, and pain relief remained constant or even improved for up to 64% of the study participants during the follow-up period of 48 weeks post-treatment.

“Severe plantar fasciitis is a chronic health issue, and it can be extremely painful--many of these men and women cannot walk or stand for a long time,” said Marcus Niewald, MD, PhD, a radiation oncologist at Saarland University Medical Center (Homburg/Saar, Germany), and one of the study’s authors. “Radiation therapy has been used for its anti-inflammatory effect for more than 60 years. We are extremely encouraged by the results of our research because evidence of improved quality of life for patients is clearly evident with the standard dose regimen.”

This study was a prospective, randomized trial of a total of 66 patients, with assessment every six weeks until 12-months post treatment. Four patients were secondarily excluded after the trial began; 29 patients received a standard dose regimen, and the remaining 33 patients received a low dose of radiation therapy. The standard dose patients were treated with a total dose of 6.0 Gy, applied in six single fractions of 1.0 Gy twice weekly on nonconsecutive days. The low dose arm received 0.6 Gy, applied in six single fractions of 0.1 Gy twice weekly on nonconsecutive days.

Related Links:

Saarland University Medical Center




Gold Member
Neonatal Heel Incision Device
Tenderfoot
Biochip Array Technology
Evidence MultiSTAT Drugs of Abuse Urine Multiplex Panel
Immobilization System
Cranial 4Pi Immobilization
Medical Adhesive
MED 5570U
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to HospiMedica.com and get access to news and events that shape the world of Hospital Medicine.
  • Free digital version edition of HospiMedica International sent by email on regular basis
  • Free print version of HospiMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of HospiMedica International in digital format
  • Free HospiMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Surgical Techniques

view channel
Image Cedit: Shutterstock

New Light-Activated Platform Advances Glioblastoma Surgery and Postoperative Treatment

Glioblastoma, an aggressive primary brain tumor, infiltrates healthy tissue and resists complete surgical removal. Residual microscopic disease and the blood–brain barrier limit the effectiveness of adjuvant... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.